You are viewing a preview of...

ASK1 inhibitors as Potential Pan-antiviral Drugs

For limiting SARS-CoV2 replication and pro-inflammatory cytokine production

Background

Apoptosis signal-regulating kinase 1 (ASK1), a MAPK kinase, is activated in response to pro-inflammatory stimuli, reactive oxygen species, and various other cellular stressors. Previous clinical studies have targeted ASK1 as a treatment for diabetic kidney disease, liver disease, or hypertension.

Technology Overview

McMaster researchers have, for the first time, identified ASK1 inhibitors (such as GS444217 and Selonsertib) as pan-antiviral inhibitors. The novel findings demonstrate that ASK1 is required during viral replication, as it limits cytokine production such as IL6, TNF alpha, and IL8. ASKI inhibition demonstrates antiviral properties against a wide range of viruses, including SARS-CoV-2.

Log in or create a free account to continue reading